Thu, Jul 24, 2014, 2:13 AM EDT - U.S. Markets open in 7 hrs 17 mins


% | $
Click the to save as a favorite.

Exelixis, Inc. Message Board

  • wilderguide wilderguide Aug 22, 2013 5:14 PM Flag

    Pazopanib vs Sunitinib in mRCC

    Published today in the NEJM.- P3 COMPARZ results. I begin to think that the P2 NIH study comparing Comet to Sutent may be an outdated venture. These non-inferior efficacy vs superior QOL results could sway the SOC favorably toward Pazo. Ernie...have any thoughts on this?

    Pazopanib was noninferior to sunitinib with respect to progression-free survival (hazard ratio for progression of disease or death from any cause, 1.05; 95% confidence interval [CI], 0.90 to 1.22), meeting the predefined noninferiority margin (upper bound of the 95% confidence interval,

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • $$$$
      Pazopanib and sunitinib have similar efficacy, but the safety and quality-of-life profiles favor pazopanib. (Funded by GlaxoSmithKline Pharmaceuticals; COMPARZ number, NCT00720941.)"

      • 1 Reply to wilderguide
      • Median PFS was 8.4 months for pazopanib vs 9.5 months for sunitinib (hazard ratio [HR], 1.047) in the intention-to-treat population. “However, in the per-protocol population, median PFS was 8.4 months for pazopanib vs 10.2 months for sunitinib, which translates into a difference of almost 2 months in favor of sunitinib,” said Kwong.
        In the overall trial population, OS was similar between the two treatment groups (p=0.275). Both drugs were associated with adverse events (AEs), with fatigue and hand-foot syndrome being more frequent with sunitinib. Rates of liver function abnormalities were however higher in patients treated with pazopanib. (Table 1) Moreover, a higher percentage of patients discontinued treatment due to AEs in the pazopanib group. (Table 2)

        Sentiment: Strong Buy

3.78+0.19(+5.29%)Jul 23 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.